Hee Kap Kang, Ph.D.

Hee Kap Kang, Ph.D.


Lupus Therapy Without Toxicity

Hee Kap Kang, Ph.D.

Northwestern University
Chicago, IL
Mechanism of Low-dose Tolerance with Nucleosomal Peptide in Lupus

Dr. Kang has developed a therapy to repair a cell defect which may cause lupus. To test this therapy, Dr. Kang’s lab is studying the effects of injecting a specific peptide into a lupus-prone mouse.

The peptide therapy appears to be beneficial without any toxic effect so far, and thus might be very important in maintaining tolerance in lupus patients after remission has been induced by more toxic immunosuppressive agents. Even apparently healthy subjects and family members of lupus, who might be at risk of developing lupus (as predicted by genetic and biomarkers) might benefit from the peptide therapy.

This is the second year ANRF has funded Dr. Kang’s work. In recognition of his exemplary studies, he has been awarded the honor of being named the first James Klinenberg Scholar. James Klinenberg, M.D., was a founding member of the ANRF Scientific Advisory Board, past president of the American College of Rheumatology, and world-renowned researcher and clinician in rheumatic diseases. Sadly, Dr. Klinenberg died in 1999.

Article Author
Arthritis National Research Foundation

The Arthritis National Research Foundation's mission is to provide initial research funding to brilliant, investigative scientists with new ideas to cure arthritis and related autoimmune diseases. Writing articles about the patients affected and the science being done to find a cure shows why we need to come together to #CureArthritis!

No Comments

Sorry, the comment form is closed at this time.